Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes

Table 1

Demographics ITT Population.

Demographics	VAL-Placebo	Placebo-VAL
No. of subjects	35	35
Female gender, 𝑛 (%)	22 (63)	27 (77)
Mean Age, years (SD), range	29 (9), 18–49	33 (10), 20–58
White, 𝑛 (%)	19 (54)	17 (49)
Black, 𝑛 (%)	13 (37)	15 (43)
HSV-1^a and HSV-2 Antibody Positive, 𝑛 (%)	17 (49)	19 (54)
HSV-1 Antibody Positive, HSV-2 Antibody Negative, 𝑛 (%)	2 (6)	1 (3)
HSV-1 Antibody Negative, HSV-2 Antibody Positive, 𝑛 (%)	13 (37)	12 (34)
HSV-1 and HSV-2 Antibody Negative, 𝑛 (%)	3 (9)	3 (9)

^aOne patient in each treatment group had an HSV-1 equivocal result and are included here.